Lioprotein (a)(Lp (a)) is a LDL-like particle with a glycoprotein called apolipoprotein (a) attached to its apoliporotein B-100 through disulfide bond. Many cases control studies have suggestedd that Lp (a) is strongly linked with atherogenesis
and
is
an independent risk factor for coronary heart disease. This study was conducted to asses the seurm concentration of Lp (a) and its relationship between various biochemical parameters in 186 patients with chronic renal failure and 81 control
subjects.
Serum cholesterol levels were higher in CAPD patients and lower in hemodialysis patients than in control subjects (p<0.05, 206±40.7 & 147.5±33.9 vs. 174.3±51.0 mg/dl). Serum triglyceride levels were higher in predialysis and CAPD patients than
in
control subjects (p<0.05, 150.8±67.0 & 149.0±78.7 vs. 115.2±52.5 mg/dl). Serm HDL-cholesterol levels were significantly lower in predialysis, hemodialysis and CAPD patients than in control sbjects (p<0.05, 34.8±8.1, 26.8±7.7 & 37.8±11.2 vs.
44.8±11.5 mg/dl, respectively). Serum LDL-cholesterol level was lower in hemodialysis patients than in control subjects (109.7±36.45 vs. 123.1±89.1 mg/dl), but the other patients didn't show significnat differences. Mean and median serum Lp
(a)
conentrations (in mg/dl) were significatnly higher in predialysis, hemodialysis and CAPD patients than in control subjects(p<0.05, 37.2±28.5934.5), 48.9±130.8(18.0), 21.3±29.8(13.5) vs. 8.9±8.3(6.9) mg/dl respectively). The distribution of Lp
()
34.7% OF CONTROL SUBJECTS (P<0.05). Thirteen and one half percent dof CAPD patients had a Lp(a)>30 mg;/dl compared to 3.7% for control subjects (p=0.0503). Correlation analysis were performed between Lp (a) and other variables. There were no
signkificnat correlations bedtween Lp (a) concenttration and other variables in all groups except BUN in hemodialysis patients (p<0.05, r=0.3183). Serum Apo AI was significantly lower in predialysis, hemodialysis and CAPD patients than in control
subjects (p<0.05, 146.9±41.0, 105.3±40.5 vs. 172.1±43.4 mg;/dl, respetively). Seum Apo B was significatnly higher in predialysis and lower in hemodialysis patients than in control subjects (p<0.05, 150.8±49.2, 102.0±32.8 vs. 119.8±31.5
mg/dl,
respectively0 and there were no significant differences between CAPD and control subjects. These resluts suggest that Lp (a) levels were increasedd in chronic renal failure patients and may increase the risk for coronary artery disease. And also,
predialysis patients had a higher percentage of Lp (a).30mg/dl compared with hemodialysis and CAPD patients. These findings suggest that the kidney plays a certain role in the removal of Lp (a). However further siudies are needed to evaluate the
role of
kidney to remove serum LP (a).
|